Jared Kaltwasser

A new report builds on previous research that could help scientists better understand type 1 diabetes (T1D) risk.

However, investigators said there is some evidence suggesting attention-deficit/hyperactivity disorder may be more common in certain age groups of children with hemophilia.

A 68-year-old man was diagnosed with ocular myasthenia gravis after presenting with double-vision and photophobia.

A new report finds secondary immunodeficiency disease (SID) also increases the risk of mortality in patients with B-cell malignancies.

A new report says early evidence of using gene therapy to treat monogenic diseases offers reason for optimism.

Patients with type 1 diabetes (T1D) reported improved glucose outcomes, but they also said their sleep and quality of life benefited.

The findings show exercise-induced hypertension increases myocardial oxygen demand.

New therapies are helping patients, but are also driving up overall costs of care.

Physicians treated the patient without surgery, although they said the patient’s case is particularly challenging and treatment was ongoing at the time of the report’s writing.

COVID-19 and worsening myasthenia gravis (MG) were the most common treatment-emergent adverse events, the study found.

The investigators said their new system makes it possible for researchers to leverage artificial intelligence even if they do not have expertise working with advanced software.

Only 11 cases of adverse events (AEs) were reported over a 6-year time frame, the investigators found, following administration of chimeric antigen receptor T-cell therapy (CAR T).

The analysis also found the therapy has a manageable safety profile.

The therapy bridges activated factors IX and X to mimic the function of missing or deficient factor VIII.

A new survey has found that most patients who have generalized myasthenia gravis who switched from eculizumab to ravulizumab preferred the latter.

Investigators say oral formulations of hypomethylating agents could be a significant advancement for people with myelodysplastic syndromes and acute myeloid leukemia.

Investigators said both reflexology and acupressure led to similar improvement in patients after 4 weeks.

Previous research links type 2 diabetes and metabolic dysfunction–associated steatotic liver disease (MASLD).

The data showed notable responses, even among patients living with chronic lymphocytic leukemia (CLL) who had previous exposure to B-cell receptor–associated kinase inhibitors, the authors said.

In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how various patient subgroups fared for complete remission (CR).

Most fragility fractures experienced by people with chronic lymphocytic leukemia (CLL) are vertebral, the study found.

Investigators reported the regimen had a tolerable safety profile, though they said its use may be limited due to the development of newer therapies.

Surprisingly, the investigators found people with uncontrolled hypertension before the pandemic actually had a slightly higher chance of getting their blood pressure under control during the crisis.

This new report helps clarify the ways in which the disease—and its treatment—affects the lives of children.

Despite potential benefits, the therapy remains in limited use for myeloproliferative neoplasms (MPNs).

The report offers new insights into the limits of the BCL2 inhibitor among patients who have myelodysplastic syndromes.

Risks like tumor lysis syndrome in the setting of chronic lymphocytic leukemia (CLL) require vigilant planning and coordination, authors say.

There is no cure for chronic lymphocytic leukemia (CLL), but new therapeutic options could extend survival, even in cases where the latest treatments have faltered.

Two strategies were tried, but neither outperformed usual care.

Treatment resistance remains a major challenge in the treatment of acute myeloid leukemia (AML), and leveraging actionable therapeutic targets is far from straightforward.